

## REVIEW ARTICLE

# Obesity Management in Primary Care: A Joint Clinical Perspective and Expert Review From OMA and ACOFP

Nicholas Pennings, DO, MFOMA, FACOFP, FAAFP<sup>1</sup>; Catherine Varney, DO, FAAFP, FOMA, DABOM<sup>2</sup>; Shaun Hines, DO, DABOM<sup>1</sup>; Bernadette Riley, DO, MS, FACOFP, DABFM<sup>3</sup>; Patricia Happel, DO, FACOFP, DABOM<sup>3</sup>; Samir Patel, BS<sup>1</sup>; Harold Edward Bays, MD, MFOMA, FTOS, FACC, FNLA, FASPC, DABOM<sup>4</sup>

<sup>1</sup> Campbell University School of Osteopathic Medicine, Buies Creek, NC

<sup>2</sup> University of Virginia School of Medicine, Charlottesville, VA

<sup>3</sup> NYIT College of Osteopathic Medicine, Old Westbury, NY

<sup>4</sup> Louisville Metabolic and Atherosclerosis Research Center and University of Louisville School of Medicine, Louisville KY

## KEYWORDS

Obesity

Primary care

Lifestyle medicine

Obesity medicine

## ABSTRACT

**Background:** This collaboration from the Obesity Medicine Association (OMA) and ACOFP examines obesity management from a primary care perspective.

**Methods:** This joint perspective is based on scientific evidence, clinical experience of the authors, and peer review by OMA and ACOFP leadership. The goal is to identify and answer sentinel questions about obesity management from a primary care perspective, utilizing evidence-based publications, and guided by expert clinical experience.

**Results:** Obesity is a disease that contributes to biomechanical complications and the most common cardiometabolic abnormalities encountered in primary care. Barriers that impede optimal care of patients with obesity in primary care include failure to recognize obesity as a disease, lack of accurate diagnosis, insufficient access to obesity treatment resources, inadequate training, insufficient time, lack of adequate reimbursement, and the adverse impact of bias, stigma, and discrimination.

**Conclusions:** Family physicians are often the first line of treatment in the healthcare setting. This affords early intervention opportunities to prevent and/or treat overweight and/or obesity. Patient care is enhanced when primary care clinicians recognize the risks and benefits of antiobesity medications (AOMs) and bariatric procedures, as well as long-term follow-up. Practical tools regarding the four pillars of nutrition therapy, physical activity, behavior modification, and medical interventions (AOMs and bariatric surgery) may assist primary care clinicians in improving the health and lives of patients with obesity.

## WHO IS THE OBESITY MEDICINE ASSOCIATION (OMA)?

OMA represents a United States-based medical society having the greatest number of physicians, nurse practitioners, physician associates, and other clinical experts (i.e., over 5000 members at time of print) engaged in the management of patients with the disease of obesity. <https://obesitymedicine.org/>

### CORRESPONDENCE:

Pennings | pennings@campbell.edu

Copyright© 2025 by the American College of Osteopathic Family Physicians. All rights reserved. Print ISSN: 1877-573X doi: 10.33181/17201

For potential conflicts of interest and financial disclosures, see page e16.

## WHO IS ACOFP?

ACOF is a professional medical association that represents more than 26,000 practicing osteopathic family physicians, residents, students, and other allied health professionals throughout the United States. <https://www.acofp.org/>

## IS OBESITY A DISEASE?

According to OMA, obesity is defined as a “serious, chronic, progressive, relapsing, and treatable multifactorial, neurobehavioral disease, wherein an increase in adiposity promotes adipose tissue dysfunction and abnormal fat mass physical forces, resulting in adverse metabolic, biomechanical, and psychosocial health consequences.”<sup>2</sup> (See Table 1.) Some of the key attributes that define

obesity as a disease include identifiable signs and symptoms of increased adiposity-related metabolic or mass effect dysfunction that reflect disease process impacting adipose tissue and target organs. Like many other diseases, the multifactorial origins of obesity may be genetic, developmental, behavioral, or due to infections or exposure to toxic substances. The morbidity and mortality can be mitigated, or perhaps caused to go into remission in some cases, through lifestyle changes, medical therapy, or interventional procedures. From a primary care perspective, the endocrinopathies, immunopathies, and biomechanical dysfunction of increased adiposity and obesity are among the most clinically relevant modifiable cause of type 2 diabetes mellitus (T2DM),<sup>3</sup> hypertension,<sup>4</sup> dyslipidemia,<sup>5</sup> cardiovascular disease (CVD),<sup>6</sup> thrombosis,<sup>7</sup> and/or cancer.<sup>8</sup>

TABLE 1: Obesity as a disease checklist. Obesity meets the criteria as a disease. (Adapted from 1).

DISEASE CRITERIA	OBSESITY
Diagnosed by:	
Signs and symptoms of illness, sickness, or ailment	✓
Adverse anatomic changes to an organ or system of the body	✓
Dysfunction of an organ or system of the body	✓
Contributes to:	
Increased morbidity	✓
Increased mortality	✓
Caused by:	
Genetic or development errors	✓
Inflammation or infection	✓
Poisons, toxicity, or adverse side effect of pharmaceuticals	✓
Nutritional abnormalities	✓
Unfavorable environmental or behavioral factors	✓
Treated by:	
Medical nutrition therapy	✓
Routine physical activity	✓
Behavior modification	✓
Medication	✓
Surgery and endoscopic procedures	✓
Patient education and training	✓
Lipid Panel	
Primary care clinicians	✓
Specialists	✓
Multidisciplinary team	✓

## WHY IS IT IMPORTANT FOR FAMILY PHYSICIANS AND OTHER PRIMARY CARE CLINICIANS TO EFFECTIVELY MANAGE PATIENTS WITH OBESITY?

Obesity is a chronic disease that affects over 40% of adults in the United States, nearly 2.5 billion adults worldwide, with CVD being a leading cause of death among patients with obesity.<sup>9-10</sup> In the United States, the total direct and indirect annual costs of obesity are estimated to be \$400 billion.<sup>11</sup> Genetics, community, behavior, and environmental factors (e.g., cumulative stress) may influence obesity and its complications, with disparities often reported based on race/ethnicity, sex, gender and sexual identity, and socioeconomic status.<sup>12-17</sup>

Based on clinic visit coding, it is estimated that approximately 8% of primary care visits involve the management of overweight and obesity.<sup>18</sup> However, this is likely a gross underestimation due to challenges with coding data in the clinic setting. Often, clinicians are not reimbursed for services related to obesity management alone. This may contribute to the variance of the diagnosis of obesity based on coding versus chart review.<sup>19</sup> Estimates suggest that as few as 30.6% of patients with body mass index (BMI) >30 kg/m<sup>2</sup> had acknowledgement of the patient's body composition in the patient visit records,<sup>20</sup> with as few as 5.6% of patient records including obesity in the problem list, despite meeting objective criteria of obesity.<sup>21</sup> Proper coding alone for obesity may have prognostic implications, in that documentation of an obesity diagnosis may be independently predictive of at least 5% weight reduction among patients with obesity; thus, acknowledging obesity as a diagnosis may be an important step in managing obesity as a disease.<sup>22</sup>

Another challenge in assessing the true impact of increased adiposity on patient management in primary care is that, as previously noted, obesity contributes to the onset and worsening of the most common metabolic diseases encounter in primary care, such as T2DM,<sup>3</sup> hypertension<sup>4</sup>, dyslipidemia,<sup>5</sup> and thrombosis,<sup>7</sup> as well as other common complications of obesity such as sleep apnea,<sup>23</sup> mental stress,<sup>24</sup> CVD,<sup>25</sup> cancer,<sup>8, 26</sup> and increased mortality and disability-adjusted life-years.<sup>25</sup> In short, irrespective of what may be reflected by coding alone, many primary care clinicians manage patients with the disease of obesity and its complications as the most common cause of clinician office visits; thus, increased adiposity might best be considered a diagnostic and management priority for many medical encounters.<sup>27</sup>

It is estimated that a two-point increase in BMI may reduce average life expectancy by 1 year, suggesting that a BMI of 30-35 kg/m<sup>2</sup> may decrease life expectancy by 2-4 years,

and a BMI of 40-45 kg/m<sup>2</sup> may decrease life expectancy by 8-10 years.<sup>28-30</sup> Conversely, among patients with obesity, reducing body weight can often reduce morbidity and mortality. Specifically in patients with preobesity/overweight or obesity and T2DM, the most consistent aspect of healthful dietary intake that contributes to T2DM remission is the degree that a healthful nutrition intervention results in weight reduction, irrespective of the evidence-based diet type.<sup>3</sup> Similarly, the most consistent factor resulting in T2DM remission with a structured weight management program or bariatric surgery is weight reduction.<sup>3</sup>

In a broader sense, among individuals with obesity, 5% weight reduction may improve risk factors for CVD, with weight reduction of >10%-15% contributing most consistently to improvement in sleep apnea, reduction in new-onset T2DM,<sup>31</sup> reduction in metabolic dysfunction-associated steatohepatitis (MASH), reduction in CVD risk, and reduction in overall mortality,<sup>32, 1</sup> as well as preventing progression of T2DM.<sup>31</sup> Unfortunately, some studies estimate that only 40% of adults with obesity or overweight receive counseling for weight reduction during encounters with clinicians.<sup>33</sup>

HOW IS OBESITY DIAGNOSED?

Common BMI criteria for overweight and obesity include<sup>2</sup>:

- BMI ≥25 kg/m<sup>2</sup> = overweight or preobesity.
- BMI ≥30 kg/m<sup>2</sup> = obesity.
- Central obesity = waist circumference ≥40 inches (102 cm) for males and ≥35 inches (88 cm) for females.

These diagnostic criteria may not apply to all patients. For example, among Asian individuals,<sup>16</sup> criteria may include:

- BMI ≥23-24.9 kg/m<sup>2</sup> = overweight or preobesity.
- BMI ≥25 kg/m<sup>2</sup> = obesity.
- Central obesity = waist circumference ≥35.4 inches (90 cm) for Asian males; ≥31.5 inches (80 cm) for Asian females.

BMI and even waist circumference can be misleading, especially when considering individuals from different sex, racial, and ethnic subgroups.<sup>35, 14, 16, 15, 13</sup> Percent body fat is a more accurate measure of adiposity. (See Table 2). Even then, percent body fat does not reflect body fat distribution. While percent body fat may be diagnostic, it may not be the best prognostic measure of adiposity-related disease. At least with regard to CVD risk, it is the accumulation of visceral fat<sup>34</sup> that best reflects adipose tissue dysfunction (adiposopathy) and best correlates with future CVD risk.<sup>36, 14</sup>

TABLE 2: OMA percent body fat diagnostic criteria, as assessed by dual X-ray absorptiometry (DXA). (Table copied from reference 34).

Obesity Medicine Association Classifications of Percent Body Fat in Adults Assessed by DXA		
	WOMEN	MEN
Essential fat	<15%	<10%
Athlete	15–19%	10–14%
Fitness	20–24%	15–19%
Acceptable	25–29%	20–24%
Pre-obesity	30–34%	25–29%
Obesity	≥35%	≥30%

WHAT BARRIERS EXIST THAT IMPAIR OBESITY MANAGEMENT? (SEE FIGURE 1)

Patient factors

Patient experiences with weight stigma and bias negatively affect patient care. Perceived negative judgment based on patient body weight from primary care providers diminishes patient trust and can adversely impact quality of care.<sup>37</sup> Patient stress associated with weight stigma can trigger counterproductive coping strategies producing unwanted outcomes such as increased caloric consumption.<sup>38-39</sup> People with increased body weight may avoid care or switch clinicians due to stigmatizing experiences and poor communication with treating clinicians,<sup>40</sup> which in turn, may result in decreased patient satisfaction, less adherence to treatment plans, and maladaptive lifestyle responses that may contribute to worse health outcomes.<sup>40</sup> Weight stigma and bias among healthcare clinicians are best replaced by advocacy to seek and achieve positive change in policy, environment, and societal attitudes, as well as to “enhance public awareness, promote prevention, advance clinical research, develop safe and effective evidenced-based therapeutic interventions, and facilitate patient access to comprehensive and compassionate treatment of the complex disease of obesity.”<sup>41</sup> Practical examples of individual advocacy are the use of people-first language, avoidance of staff jokes and phrases offensive to patients with obesity, and availability of obesity-appropriate office environment and equipment.<sup>41</sup>

People with obesity (PwO) may not recognize that they have obesity. In the Awareness, Care and Treatment in Obesity Management (ACTION) study, only 50% of PwO saw themselves as having obesity.<sup>42</sup> While 60% acknowledged that obesity was a disease, only 54% were concerned that it might affect their health. Additionally, PwO might not expect their primary care provider to address their body weight, as the same study showed that 82% of patients felt they were the ones completely responsible for their weight loss reduction.<sup>42</sup>

Psychosocial factors can impact the management of obesity. Lifestyle changes command significant patient


time, effort, and expense. Long work hours and night-shift work are associated with obesity. A National Health and Nutrition Examination Survey (NHANES) analysis found that working >40 hours per week increased the risk of obesity by 40%.<sup>43</sup> Obesity is more prevalent in low-income populations, potentially due to limited access to healthful foods, limited education regarding healthful foods, physical inactivity, mental stress, and other environmental factors.

(<https://www.cdc.gov/obesity/data-and-statistics/adult-obesity-prevalence-maps.html>; <https://www.cdc.gov/nchs/products/databriefs/db50.htm>).<sup>44</sup> Furthermore, some evidence supports that while low socioeconomic factors may contribute to obesity, obesity may also contribute to lower income (i.e., reverse causality).<sup>45</sup> Mental health factors like depression, anxiety, or stress may also negatively impact a patient's body weight.<sup>24</sup>

**FIGURE 1: Patient barriers to optimal obesity management.** Care of individuals with obesity can be impaired due to lack of access to nutritional and physical activity education and monitoring, behavior modification counseling, antiobesity pharmacotherapy, and/or bariatric surgery/procedures. Bias, stigma, and discrimination can also contribute to inadequate care of individuals with obesity.



**FIGURE 2: Adverse health consequences of clinician weight bias and stigma.** Many healthcare clinicians hold negative attitudes and stereotypes about people with obesity. Such attitudes affect person-perceptions, judgment, interpersonal behavior, decision making, and may adversely impact the quality of care clinicians provide and patients receive. Past experiences of poor treatment or anticipation of poor treatment may contribute to patient stress, avoidance of care, mistrust of clinicians, poor adherence, and adverse health outcomes among patients with obesity. (Copied from reference <sup>41</sup>).to inadequate care of individuals with obesity.



## Clinician factors

Several clinician factors may present barriers to optimal treatment of obesity. Some clinicians may have bias and negative stereotypes regarding patients who have obesity. (See Figure 2).

Other clinicians may not have the educational background and/or training<sup>46</sup> to appreciate the breadth of obesity as a disease and how the adiposopathic consequences of obesity contribute to endocrinopathies and immunopathies, often leading to the most common reasons for primary care clinician encounters.<sup>47</sup> Primary care clinicians may also lack sufficient resources for optimal obesity management, including inadequate time for medical visits of patients with obesity who often have multiple medical complications. Finally, primary clinicians may not be adequately reimbursed for obesity management,<sup>48</sup> disincentivizing physicians from spending the time needed for the optimal treatment of obesity.

## HOW CAN A NURSE OR MEDICAL ASSISTANT CONTRIBUTE TO OPTIMAL OBESITY MANAGEMENT?

OMA has published a series of tables with itemized listings relevant to medical practice obesity management that include: practice summary, business startup, equipment, services, practice priorities and philosophies, policies

and procedures, standard operating procedures, patient materials, certifications and ongoing training, as well as discussion of obesity-relevant aspects of tele-/video health encounters.<sup>2</sup> Additionally, tasks that may be undertaken by a nurse or medical assistant prior to the clinician encounter include:

- Assessment for accurate and thorough completion of patient intake forms for medical practices using electronic health records, which may be especially important in anticipation of possible future preauthorization approval for AOMs.<sup>49</sup>
- Administration of obesity-related questionnaires for underlying psychiatric disease or eating disorders.<sup>50</sup>
- Accurate assessment of baseline health metrics (e.g., height, weight, waist circumference, blood pressure, and heart rate).<sup>2</sup>
- Unbiased preliminary discussion of body weight goals, lifestyle modification (e.g., dietary guidance, physical activity monitoring), behavior modification, as well as education on the benefits and risks of AOMs and bariatric surgery.
- Utilization of motivational interviewing techniques, which may improve the effectiveness of nursing guidance to patients with obesity.<sup>50</sup>
- Provide follow-up contacts to support an obesity treatment plan.

## AMONG ADULTS WITH OBESITY, WHAT ARE THE SPECIFIC BENEFITS OF WEIGHT REDUCTION ON PATIENTS WITH “SICK FAT DISEASE” OR ADIPOSOPATHY (E.G., CARDIOMETABOLIC DISEASE, CVD, AND CANCER) AND “FAT MASS DISEASE” (E.G., SLEEP APNEA, OSTEOARTHRITIS)?

### Sick fat disease (adiposopathy)

Adipose tissue is the organ that stores the greatest amount of body energy. However, excessive positive caloric balance may lead to adipocyte hypertrophy and dysfunction, as well as adipose tissue expansion and dysfunction (i.e., adiposopathy), which contributes to the development of insulin resistance, elevated blood glucose,<sup>3</sup> elevated blood pressure,<sup>4</sup> elevated atherogenic blood lipids,<sup>5</sup> and CVD,<sup>53</sup> and cancer.<sup>8</sup> Moderate weight loss of 5%-10% improves metabolic disease. Compared to changes in BMI, the reduction of cardiometabolic risk factors and cardiometabolic risk may be better reflected by reductions in visceral fat.<sup>54, 36</sup> Figure 3 shows the categories of obesity complications that include “sick fat disease” (adiposopathy) and “fat mass disease.” Table 3 demonstrates the predicted health benefits of weight reduction in patients with obesity.




TABLE 3: Estimated degree of mean weight reduction associated with clinically meaningful improvement in illustrative health outcomes.<sup>32</sup>  
(Copied from reference 52.)

Degree of Weight Reduction Associated With Improvement in Health Condition	Medical Conditions
>2.5% weight reduction	<ul style="list-style-type: none"><li>• Improvement in glucose metabolism</li><li>• Reduction in triglyceride blood levels</li><li>• Improvement in polycystic ovary syndrome and infertility</li></ul>
>5.0% weight reduction	<ul style="list-style-type: none"><li>• Improvement in impact on weight on quality of life score</li><li>• Improvement in depression</li><li>• Improvement in mobility</li><li>• Improvement in knee functionality, as well as improvement in walking speed, distance, and pain among patients with knee</li><li>• osteoarthritis</li><li>• Reduction in hepatic steatosis</li><li>• Improvement in urinary incontinence</li><li>• Improvement in sexual function</li><li>• Increase in high-density lipoprotein cholesterol levels</li><li>• Improvement in healthcare costs</li></ul>
>10% weight reduction	<ul style="list-style-type: none"><li>• Improvement in sleep apnea</li><li>• Improvement in nonalcoholic steatohepatitis (NASH)*</li></ul>
>15% weight reduction	<ul style="list-style-type: none"><li>• Potential reduction in cardiovascular and overall mortality</li></ul>

\*The more current term for nonalcoholic steatohepatitis (NASH) is metabolic dysfunction-associated steatohepatitis (MASH).

FIGURE 3: Metabolic and fat mass complications of obesity. Obesity can have metabolic and mechanical adverse consequences, including endocrine/metabolic consequences and pathogenic issues related to biomechanics. (Adapted from reference 2). For example, an important adiposopathic consequence of obesity is metabolic dysfunction–associated steatohepatitis (MASH).<sup>51</sup>



Fat mass disease

Excess weight can increase mechanical forces on joints and compresses tissues affecting respiration, renal perfusion, and skin integrity. The excessive load on knee joints due to obesity may induce stress and malalignment that contributes to osteoarthritis; weight reduction has the potential to reduce knee pain among patients with obesity.<sup>55</sup> Increased visceral adipose tissue and perirenal fat may compress the kidneys, increasing renal tubular absorption of sodium, and thus increasing blood pressure.<sup>56</sup> Adverse integumentary effects of obesity include mechanical friction, infections, and hypertrophic changes.<sup>57</sup>

SHOULD PRIMARY CARE PHYSICIANS HAVE SEPARATE WEIGHT-RELATED VISITS TO HELP MANAGE OBESITY?

Among patients with obesity, some data suggest that only about 25% of patients are offered a weight-management treatment plan,<sup>20</sup> possibly because the clinician prioritizes the management of other concomitant diseases. This suggests the potential benefit of dedicated weight-related clinician visits. For patients with obesity, structured weight management in primary care may improve weight reduction.<sup>58</sup> Incorporating group visits and virtual visits to address weight management can be an effective tool to treat obesity in a primary care setting. <https://info.primarycare.hms.harvard.edu/perspectives/articles/integrating-weight-management-in-primary-care>

## WHAT ARE THE EFFECTS OF PHYSICIAN COUNSELING ON LIFESTYLE CHANGES ON WEIGHT LOSS?

While individual patient responses may vary, data suggests that overall, primary care clinicians can be successful in assisting patients in achieving and maintaining weight loss (i.e., ~5% weight loss) through intensive counseling regarding lifestyle modifications on a scheduled timeframe.<sup>59</sup> Greater weight reduction usually requires AOMs<sup>52, 60</sup> and/or bariatric surgery.<sup>61</sup>

## WHAT ARE THE BENEFITS OF PROVIDING NUTRITIONAL THERAPY IN PATIENTS WITH OBESITY?

The objective of nutritional intervention for patients with obesity often depends on the concomitant treatment plan. That said, common principles that apply, irrespective of the concomitant obesity treatment plan include:

- Incorporating dietitians in primary or outpatient care, which improves coordination of care and compliance with attending multiple sessions with the dietitian in the future.<sup>62</sup>
- Assessing potential eating behaviors as well as limiting the intake of energy-dense foods and portion control.
- Increasing the consumption of healthful foods such as fruits and vegetables.<sup>63</sup>

Overall, modifying dietary intake is an integral component of obesity management. A healthful dietary routine can improve metabolic health and reduce the risk of inflammation and noncommunicable diseases.<sup>62</sup>

The emphasis of dietary recommendations may differ when nutritional intervention is intended to be the primary mode or main driver of weight reduction among patients with overweight or obesity. In this case, the dietary intake must achieve a sufficient amount of negative caloric balance to promote clinically meaningful weight reduction.<sup>64, 1</sup> However, among patients treated with highly effective AOMs or bariatric surgery, the emphasis of nutrition intervention and physical activity may shift from achieving further weight loss to maintaining overall health and supporting long-term outcomes. For example, in patients treated with highly effective AOMs, the emphasis may shift to mitigating the muscle mass loss and macro-/micronutrient deficiencies (i.e., protein) commonly associated with substantial weight reduction.<sup>65</sup> This may be especially important in patients with obesity at risk for sarcopenia with weight reduction.<sup>66</sup> Another priority among patients treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is adequate hydration to avoid increases in creatine and blood urea nitrogen. The potential for GLP-1 RA-related dehydration is increased

with nausea, vomiting, decreased food intake (many foods contain water), as well as potential decreased fluid intake with GLP-1 RAs,<sup>67</sup> with some reports suggesting this is at least partially due to decreased thirst.<sup>68</sup>

## IS IT FEASIBLE FOR FAMILY PHYSICIANS TO PROVIDE NUTRITIONAL COUNSELING DURING A PATIENT ENCOUNTER?

Primary care clinicians face practical challenges when engaging in nutritional intervention for patients with obesity, which include:<sup>69</sup>

- Inadequate training in nutritional therapy.
- Insufficient time to implement and monitor nutritional therapy.
- Lack of interest in providing nutritional therapy.
- Lack of reimbursement of nutritional therapy.

That said, many primary care clinicians can incorporate nutritional and physical activity recommendations through a commitment to education, and by focusing on essential principles. Examples of simple ways for primary care clinicians to assess and make recommendations regarding nutritional and physical activity include:

- Recommend the patient keep a dietary diary, recording everything they eat and drink for a week. Schedule a follow-up weight-specific visit to review the diary and discuss any dietary concerns.
- Convey basic nutritional principles to the patient with obesity who may also be at risk for CVD and cancer that include:<sup>70</sup>
  - Prioritize:
    - Vegetables, fruits, legumes, nuts, whole grains, seeds, and fish.
    - Foods rich in monounsaturated and polyunsaturated fats such as fish, nuts, and nontropical vegetable oils.
    - Soluble fiber.
  - Limit:
    - Saturated fat.
    - Excessive sodium.
    - Cholesterol in patients at high risk for CVD with a known increase in serum cholesterol.
    - Ultra-processed carbohydrates.
    - Sugar-sweetened beverages.
    - Alcoholic beverages.
  - Avoid all trans fats.
- Provide more granular nutritional advice. For example, the two meal plans having the most evidence in reduction of cardiovascular risk and other health benefits are the Mediterranean Diet and the “Dietary Approaches to Stop Hypertension” (DASH) diet.<sup>64</sup>
- Refer to a registered dietitian for more in-depth nutritional counselling.

## WHAT TYPE OF IMPACT AND HOW MUCH IMPACT DO BEHAVIORAL MODIFICATIONS HAVE ON PATIENTS WITH OBESITY?

Intensive behavioral therapy has varying definitions. Irrespective of the specific behavior therapy plan, the overall intent is to provide nutritional and physical activity guidance at increased effort, frequency, and duration compared to conventional nutritional and physical activity guidance. Intensive behavior therapy may result in 8%-10% mean weight loss compared to the patient's initial weight,<sup>71</sup> with evidence supporting a reduction in the risk of CVD and T2DM,<sup>31</sup> as well as less weight regain after initial weight reduction among those with obesity.<sup>72</sup> Patients with obesity who have higher adherence rates to visits and behavior changes (in reference to their weight management) are more likely to experience greater weight reduction after bariatric surgery.<sup>73</sup>

## IS IT FEASIBLE FOR FAMILY PHYSICIANS TO COUNSEL PATIENTS ON BEHAVIORAL MODIFICATION DURING AN ENCOUNTER?

Primary care clinicians face practical challenges when engaging in nutritional intervention for patients with obesity, which include:<sup>74</sup>

- Lack of adequate training in behavioral therapy.
- Lack of adequate time to provide behavioral therapy.
- Lack of interest in providing behavioral therapy to patients with obesity.
- Lack of reimbursement for behavioral therapy.

That said, most primary care clinicians do have a reasonable opportunity to implement rudimentary approaches, such as:<sup>50, 75-76</sup>


- Include eating disorder questionnaires in the intake forms in electronic health records.
- Utilize basic motivational interviewing techniques.
- Apply basic cognitive behavioral therapy and/or acceptance-based therapy techniques.
- Employ SMART goals (**S**pecific, **M**easurable, **A**chievable, **R**elevant, and **T**ime-related).
- Refer to a behavioral therapist.

## WHAT ARE THE BENEFITS OF PHYSICAL ACTIVITY IN PATIENTS WITH OBESITY?

Figure 4 describes OMA's goals for physical activity, which are similar to the physical activity goals of other medical societies. The major difference is the explicit inclusion of over 5000 steps per day.<sup>64</sup> That is because for many,

walking is the most common form of routine physical activity, with less than 5000 steps per day considered sedentary. A greater number of steps per day (i.e., >10,000 steps per day) is associated with greater weight reduction<sup>78</sup> among patients with obesity.

**FIGURE 4: OMA's physical activity goals.** OMA's physical activity goals include steps per day, specified exercise intensities and durations, and recommended resistance training sessions per week. OMA's physical activity goals specifically include steps to achieve daily dynamic physical activity goals, with even greater aerobic activity providing additional health benefits. (Copied from reference 77.)



It is estimated that the average number of steps for US adults is less than 4000 steps per day.<sup>64</sup> While a higher number of steps per day helps achieve improved health outcomes, even minimal to modest physical activity is more healthful than no physical activity. A meta-analysis suggests that above 4000 steps per day is the threshold for detectable reduction in all-cause mortality and only slightly over 2000 steps per day is the threshold for a detectable reduction in cardiovascular mortality.<sup>79</sup> Given that patients with obesity often have physical inactivity and/or physical or other limitations that make achieving 10,000 steps per day a challenge, OMA chose an initial recommendation of 5000 steps per day as a reasonable balance between evidenced-based health benefits, and achievability. Furthermore, this is only an initial recommendation, with hopes that following effective and sustained obesity management, the number of steps per day can be increased.

For those able and willing to increase their physical activity, combining aerobic training alone and/or resistance training during a weight-reduction nutritional plan may modestly enhance fat weight reduction.<sup>80</sup> Equally important, physical activity or moderate-intensity aerobic exercise ( $\geq 250$  min/week) after weight reduction allows for greater success in weight reduction maintenance.<sup>80</sup> Beyond the modest improvement in weight reduction, (and/or weight maintenance following weight loss), exercise training programs will also improve insulin sensitivity, hypertension, and intrahepatic fat in adults with obesity, with or without accompanying T2DM.<sup>80</sup>



It is often noted that, in the treatment of obesity, the primary benefit of routine physical activity is maintaining weight reduction rather than substantially contributing to initial reduction in weight. Additionally, Table 4 highlights other health benefits of routine physical activity that extend beyond maintenance of body weight. Furthermore, routine physical activity incorporating resistance exercise is an important intervention that may limit the loss of lean body mass during weight reduction, thus helping to mitigate sarcopenia.<sup>66</sup>

TABLE 4: Beyond its favorable effects on body weight and body composition, routine physical activity has multiple health benefits applicable to the patient with obesity. (Copied from reference 1).

Illustrative benefits of routine physical activity/exercise.	
Body weight and composition:	Metabolic benefits:
<ul style="list-style-type: none"> <li>Facilitates weight reduction</li> <li>Helps maintain weight reduction</li> <li>May increase muscle mass</li> <li>May reduce percent body fat</li> </ul>	<ul style="list-style-type: none"> <li>Improve insulin sensitivity</li> <li>Reduce hyperglycemia</li> <li>Improve blood lipids</li> </ul>
Cardiovascular benefits:	Cancer benefits:
<ul style="list-style-type: none"> <li>Decrease sympathetic activity</li> <li>Decrease blood pressure</li> <li>Reduce heart rate</li> <li>Reduce risk for cardiac dysrhythmias</li> <li>Improve autonomic balance</li> <li>Enhance fibrolysis</li> <li>Enhance coronary dilation capacity</li> <li>Facilitate myocardial cellular regeneration</li> <li>Increase myocardial oxygen utilization</li> <li>Improve endothelial function</li> <li>Reduce myocardial and plaque inflammation</li> </ul>	<ul style="list-style-type: none"> <li>Reduce risk of cancer onset</li> <li>Reduce risk of cancer recurrence</li> <li>Inhibits cancer cell proliferation</li> <li>Increase cancer cell apoptosis</li> <li>Reduce inflammation</li> <li>Enhance effectiveness of cancer treatment</li> <li>Counteract cancer and cancer treatment complications</li> </ul>
Sleep benefits:	Neuromusculoskeletal benefits:
<ul style="list-style-type: none"> <li>Reduce time to sleep</li> <li>Reduce wake time during nighttime</li> <li>Reduce daytime sleepiness</li> <li>Possible reduction in sleep medications</li> </ul>	<ul style="list-style-type: none"> <li>Improve muscle strength</li> <li>Improve bone strength</li> <li>Improve balance and coordination</li> <li>Reduce risk of dementia</li> <li>Reduce depression</li> <li>Reduced anxiety &amp; improved mood</li> </ul>

IS IT FEASIBLE FOR FAMILY PHYSICIANS TO COUNSEL PATIENTS ON PHYSICAL ACTIVITY IN THE CLINICAL SETTING?

Primary care clinicians face practical challenges when recommending physical activity for patients with obesity, which include:<sup>81</sup>

- Lack of adequate training in physical activity recommendations.
- Lack of adequate time to provide physical activity recommendations.

- Lack of interest in providing physical activity recommendations.
- Lack of reimbursement for physical activity recommendations.

That said, most primary care clinicians do have a reasonable opportunity to implement rudimentary approaches to physical activity advice, such as:

- Write an “exercise prescription”, such as FITTE: <sup>77, 46</sup>
  - Frequency.
  - Intensity.
  - Time spent.
  - Type of activity.
  - Enjoyment.
- Use a patient-centered approach to recommend a specified number of steps per day.
- Monitor the number of steps per day, in hopes to escalate when appropriate.
- Provide alternative physical activity recommendations for patients with mobility limitations due to their physical conditions; these recommendations may include using a hand bike for patients with lower-extremity amputations.
- Refer to physical therapy or exercise physiologist.

WHAT ARE THE BENEFITS FOR PRIMARY CARE CLINICIANS TO PRESCRIBE AOMS IN COMPARISON TO IMMEDIATE REFERRAL TO AN OBESITY MEDICINE SPECIALIST?

Obesity medicine specialists are available to assist in the management of patients with obesity.<sup>46</sup> Obesity medicine specialists represent less than 1% of the physician workforce in the United States (<https://www.abom.org/stats-data-2/>). Given this limitation and given the vast number of patients with overweight and obesity, it is a clinical reality that most patients with obesity will need to be managed by primary care clinicians. Additionally, when managing health risk factors, the greatest lifetime benefit occurs with early management compared to implementing treatment in the late stages of a disease.<sup>82</sup> Studies support that patients who maintain an ongoing relationship with primary care providers reduce their cardiovascular risk and lower all-cause mortality.<sup>83-85</sup>

Different weight management models are available that may help improve health outcomes for patients with obesity.<sup>58</sup> Figure 5 suggests an approach where, in the absence of acute illness, the treatment paradigm should focus on addressing the “cause” of the complications of obesity (i.e., such as elevated glucose levels in patients with prediabetes or T2DM), which in most cases, is the result of the adiposopathic endocrinopathies and immunopathies of obesity.

AOMs are one of the four pillars of obesity management.<sup>52, 86</sup> (See Table 5 and Figure 6). Phentermine is a sympathomimetic agent approved in 1959 for short-term use in the treatment of obesity. This short-term indication reflects prior limited understanding of obesity as a chronic disease and is due to the lack of longer-term data regarding potential health benefits and risks. Nonetheless, given its low cost, the manner in which phentermine is utilized (including duration of treatment) is variable among clinicians.<sup>87</sup> Electronic health record reviews suggest that the use of phentermine beyond the 12-week FDA recommendation is safe and effective.<sup>88</sup> However,

some US states restrict its long-term use and prescribers should be knowledgeable of their state's restrictions. The average weight reduction with phentermine depends on dose, duration of treatment, and accompanying behavior modification, but is approximately 7%.<sup>89</sup>


An extended-release version of phentermine plus topiramate is approved for long-term use with an average weight loss of 10%.<sup>89</sup> Bupropion plus naltrexone extended release is also approved for long-term use with an average weight loss of 5%-7%.<sup>90, 91</sup>

TABLE 5: AOMs indicated for long-term use. AOMs should be avoided with pregnancy, during lactation, or if there is a known hypersensitivity to any of the components. Orlistat is rarely used in clinical practice and was omitted from this table. For a summary of orlistat, see reference 52.


MEDICATION	PHENTERMINE/ TOPIRAMATE ER 3.75/23 →15/92 MG	BUPROPION/ NALTREXONE 90/8 MG 1 QD→2 BID	LIRAGLUTIDE 0.6 MG→3.0 MG	SEMAGLUTIDE 0.25 MG→2.4 MG	TIRZEPATIDE 2.5 MG→15 MG
Dosing	Daily	Twice daily	Daily	Weekly	Weekly
Route	Oral Scheduled IV Controlled	Oral	Injectable	Injectable	Injectable
Minimum Age	12 years	18 years	12 years	12 years	18 years
Contra-indications	Glaucoma, change in mood, cognitive impairment, metabolic acidosis, decrease in renal function, paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth	Uncontrolled hypertension, seizure disorders, anorexia nervosa or bulimia, abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs, opioid use, during or within 14 days	Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2	Personal or family history of MTC or in patients with MEN 2	Personal or family history of MTC or in patients with MEN syndrome type 2
Side effects	Glaucoma, change in mood, cognitive impairment, metabolic acidosis, decrease in renal function, paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth	Nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth and diarrhea	Nausea, diarrhea, constipation, vomiting, injection-site reactions, headache, hypoglycemia, dyspepsia, fatigue, dizziness, abdominal pain, increased lipase, upper abdominal pain	Nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with T2DM, flatulence, gastroesophageal reflux disease, and nasopharyngitis	Nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection-site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, gastroesophageal reflux disease
Reported weight loss	Oral Scheduled IV Controlled	7%	7%-8%	15%	20%

Abbreviations: BID, twice a day; ER, extended-release; IV, intravenous  
<https://qsymia.com/patient/include/media/pdf/prescribing-information.pdf> (accessed 2024)  
<https://www.curraxpharma.com/PI/Contrave-label-current.pdf/> (accessed 2024)  
<https://www.novo-pi.com/saxenda.pdf> (accessed 2024)  
<https://www.novo-pi.com/wegovy.pdf> (accessed 2024)  
<https://pi.lilly.com/us/zeptbound-uspi.pdf> (accessed 2024)

**FIGURE 5: “Treat obesity first” prioritization for patients with obesity and T2DM without acute disease.** Treatment of obesity is the priority for most patients without acute illness, especially if the therapies chosen for treatment of obesity are also expected to improve the complications of obesity. Conversely, patients with marked increases in glucose and/or blood pressure, severe dyslipidemia (e.g., severe hypertriglyceridemia), acute thrombosis, CVD, or cancer should have these acute metabolic abnormalities urgently assessed, managed, and treated, preferably with concomitant interventions that may also improve obesity. (Copied from reference 3).



**FIGURE 6: Four pillars of obesity management.** Medical interventions include AOMs and bariatric procedures.



Advances in the incretin-based class of AOMs has substantially affected the treatment landscape for obesity. Semaglutide and liraglutide are GLP-1 RAs, which mimic the GLP-1 hormone that is released in the gastrointestinal tract in response to eating. GLP-1 RAs act on satiety centers in the hypothalamus, slow gastric emptying, and stimulate glucose-mediated insulin response. Semaglutide and liraglutide are approved/indicated at lower doses to treat T2DM and approved/indicated at higher doses to treat obesity.

Liraglutide 3.0 mg per day injection was approved as an AOM in 2014 and achieves a weight reduction of >5%.<sup>52</sup> As reported in a double-blind clinical trial of nearly 2000 adults with obesity from 2021, once-weekly 2.4-mg semaglutide injection achieved an average weight reduction of 15% body weight over 68 weeks, compared to 2% weight reduction in the placebo group.<sup>92</sup> This was followed by the Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes trial (SELECT trial), which demonstrated that in patients with preexisting CVD and with overweight or obesity but without T2DM, semaglutide 2.4-mg weekly subcutaneous injection was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months—with an overall 20% relative risk reduction in cardiovascular endpoints.<sup>93</sup> Semaglutide has the following indicated uses (<https://www.novo-pi.com/wegovy.pdf>):

- To reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with established CVD and either obesity or overweight.
- To reduce excess body weight and maintain weight reduction long term in:
  - Adults and pediatric patients aged 12 years and older with obesity.
  - Adults with overweight in the presence of at least one weight-related comorbid condition.

Tirzepatide is also an FDA-approved AOM that is a GLP-1 RA and a glucose-dependent insulinotropic polypeptide (GIP) RA. Tirzepatide may reduce body weight approximately 20% at 72 weeks on a maximum dose of 15-mg injection weekly.<sup>52, 94</sup> In 2024, two phase,<sup>3</sup> double-blind, randomized, controlled trials were reported involving adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity who were not receiving treatment with positive airway pressure (PAP) at baseline. Tirzepatide not only reduced body weight, but also reduced the apnea-hypopnea index, hypoxic burden, improved sleep-related patient-reported outcomes, and reduced highly sensitive C-reactive protein and systolic blood pressure.<sup>95</sup> Tirzepatide has the following indicated uses (<https://pi.lilly.com/us/zeptbound-uspi.pdf>):

- To reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.
- To treat moderate-to-severe OSA in adults with obesity.

## WHAT CHALLENGES DO PRIMARY CARE CLINICIANS ENCOUNTER REGARDING USE OF AOMS?

AOMs are effective as part of a comprehensive plan to treat obesity. However, medication cost, limited insurance coverage, supply shortages, and side effects often complicate their use. Beyond generic AOMs and less expensive AOMs (which are generally less effective), the higher cost of AOMs often prohibits out-of-pocket payment. Compounded versions of the incretin therapies are commonly available but pose safety concerns regarding quality and purity.<sup>96-97</sup> AOMs, including semaglutide and tirzepatide, are intended to be taken long term, as weight regain often occurs after ceasing the medication.<sup>98-99</sup> For patients experiencing excessive weight reduction, additional diagnostic procedures may be indicated to evaluate for other potential causes of weight reduction, as well as to inform on potential adjustment in AOM dose if weight reduction continues after weight goal is achieved.<sup>60</sup>

Patients with higher BMIs may avoid seeking healthcare due to anxiety around being weighed or being told to lose weight.<sup>100</sup> Osteopathic family medicine physicians can address these barriers. The tenets of osteopathic medicine make osteopathic family physicians an effective bridge to overcome these barriers by developing personalized obesity care for patients. Effective obesity management requires comprehensive management practices that include counseling patients about the importance of lifestyle modifications as a complement to pharmacotherapy.<sup>86</sup> General recommendations regarding AOMs and primary care include:

- AOM should be prescribed as an adjunct to healthful nutrition, physical activity, and behavioral modification.
- Staff training is often required to navigate the prior authorizations process from insurances that do cover AOMs.
- Common side effects such as nausea, vomiting, diarrhea, constipation, and gastroesophageal reflux can often be managed by slowing dose titration, short-term use of antiemetic medications for symptom relief, and potential dose deescalation or “drug holiday” when applicable situations arise.

## HOW SHOULD FAMILY PHYSICIANS DECIDE WHICH PATIENTS TO SEND FOR BARIATRIC SURGERY CONSULTATION?

Primary care clinicians often play an essential role in the initial discussion and referral for bariatric surgery.<sup>102</sup> Patient referrals for bariatric surgery involve shared decision-making based on medical indications and patient goals. The indications commonly approved by health insurance

for adults include BMI  $\geq 40$  kg/m<sup>2</sup> or BMI  $\geq 35$  kg/m<sup>2</sup> with weight-related comorbidities, with lower thresholds for Asian populations. Indications for adolescents include BMI  $>120\%$  of the 95th percentile and major comorbidity, or BMI  $>140\%$  of the 95th percentile. Applicable health insurance websites at the time of this writing include:

- United Healthcare <https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/bariatric-surgery.pdf> (accessed 12/14/24).
- Aetna [https://www.aetna.com/cpb/medical/data/100\\_199/0157.html](https://www.aetna.com/cpb/medical/data/100_199/0157.html) (accessed 12/14/24).
- Cigna [https://static.cigna.com/assets/chcp/pdf/coveragePolicies/medical/mm\\_0051\\_coveragepositioncriteria\\_bariatric\\_surgery.pdf](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/medical/mm_0051_coveragepositioncriteria_bariatric_surgery.pdf) (accessed 12/14/24).

Bariatric surgery in adolescents in their teenage years is generally effective with sustained weight reduction a decade after their procedures.<sup>103</sup> In 2022, the American Society for Metabolic and Bariatric Surgery (ASMBS) and the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) recommended bariatric surgery for BMI  $\geq 35$  kg/m<sup>2</sup> regardless of comorbidities and for those with BMI  $\geq 30$  kg/m<sup>2</sup> and T2DM or other weight-related comorbidities that have not responded to nonsurgical methods.<sup>104</sup> For Asian populations, ASMBS/IFSO recommend bariatric surgery for BMI  $\geq 27.5$  kg/m<sup>2</sup>.<sup>104</sup>

Once the primary care physician has determined a patient is best referred for bariatric surgery, they should collaborate with the bariatric surgery team to understand and facilitate the presurgical plan. Common presurgical evaluations include a nutritional consultation, upper endoscopy, cardiac evaluations, sleep study, psychiatric evaluation, and laboratory testing including screening for common vitamin deficiencies.<sup>61, 101, 105-106</sup>

## HOW EFFECTIVE IS BARIATRIC SURGERY FOR IMPROVING CARDIOVASCULAR OUTCOMES?

Bariatric surgery is effective in improving obesity-related metabolic, cardiovascular, and cancer outcomes.<sup>61, 107-109</sup> Comparison of diabetes outcomes in patients treated with bariatric surgery versus medical/lifestyle reported a 37.5% remission rate in bariatric surgery patients compared to 2% with medication/lifestyle. Additionally, greater reductions are reported for HbA1c and fasting glucose in the surgery group.<sup>61, 110</sup> A 2021 population-based cohort study of patients with known ischemic heart disease or heart failure examined the incidence of MACE (major adverse cardiovascular events) including all-cause mortality, myocardial infarction, cerebrovascular events, and heart



**TABLE 6: Recommended baseline laboratory assessment by metabolic bariatric surgery type.**  
(Copied from reference 101).

Nutrient	Preferred test	Baseline prior to SG, RYGB	Baseline prior to SADI-S, BPD/DS
Vitamin A (retinol)	Retinol serum		x
Vitamin B1 (thiamin)	Whole blood thiamin	x	x
Vitamin B9 (folate)	Red blood cell folate	x	x
Vitamin B12 (cyanocobalamin)	B12 serum, methylmalonic acid (MMA) serum (provides early sign of B12 deficiency)	x	x
Vitamin D (D2, (ergocalciferol) or D3, (cholecalciferol))	25-OH Vit D	x	x
Vitamin E (A-Tocopherol)	Vit E serum		x
Vitamin K	Vit K serum		x
Calcium (citrate)	Calcium, ionized, serum	x	x
Copper	Copper, serum		x
Iron	Iron and iron binding capacity	x	x
Zinc	Zinc, serum		x

SG: sleeve gastrectomy; RYGB: roux-en y gastric bypass; BPD-DS: biliopancreatic diversion with duodenal switch; SADI-S: single anastomosis duodenal-ileostomy with sleeve gastrectomy; OH: hydroxy.

failure, after bariatric surgery. Compared to matched controls, the surgical group showed a 42% reduction in MACE with a 65% reduction in cardiovascular mortality.<sup>107</sup> Several studies have identified a decrease in the risk of hormone-related cancers such as breast, endometrial, and prostate cancer, while the effects on colon cancer are less clear.<sup>61</sup>

WHAT IS THE ROLE OF THE FAMILY PHYSICIAN AFTER BARIATRIC SURGERY?

Equally important is the role of primary care clinicians after patients undergo bariatric surgery. Longitudinally, it is critical that the post bariatric surgery patient undergo monitoring for macro- and micronutrient deficiencies, long-term surgical complications, psychiatric conditions, and prevention of weight regain. Multiple studies have demonstrated that long-term follow-up with the surgical team reduces drastically to 30% in 2 years and less than 10% in 10 years.<sup>111</sup> In cases where this follow-up monitoring is not adequately being done elsewhere, it is important that the primary care clinician have a working

knowledge of nutritional deficiencies that may occur after bariatric surgery, and how to treat such nutritional deficiencies.<sup>112, 61</sup> (See Table 6 and Table 7).

After bariatric surgery, it is important that nutritional and vitamin deficiencies be monitored. Although studies have shown mixed statistical results on specific vitamin deficiency seen after bariatric surgery, clinical guidelines recommend vitamin and mineral supplementation (as noted in Table 7). Periodic laboratory evaluation, including vitamin B12, folate, and iron should be monitored to prevent these vitamin deficiencies before and after surgery. Bone loss, as well as changes in sex hormones, can also occur within 24 months after bariatric surgery.<sup>113</sup> Bone mineral density testing is recommended 2 years after surgery.<sup>114</sup> Also, patients with obesity and infertility before bariatric surgery may experience improved fertility with weight reduction.<sup>115</sup> This should prompt discussions on appropriate contraception before and after surgery. After bariatric surgery, the multispecialty team should continue to focus on healthful nutrition and regular physical activity to optimize weight reduction maintenance,

minimize nutritional deficiencies, and preserve lean body mass. Psychologically, patients undergoing bariatric surgery may benefit from support groups and individual therapy as they adjust to their new lifestyle after surgery.

While it is often recommended that patients have long-term follow-up by bariatric surgeons after surgery, some patients may discontinue their regular clinic and laboratory follow-up. In a 10-year follow-up study of patients receiving bariatric surgery, only 40% of patients had sufficient follow-up data at 10 years.<sup>116</sup> Monitoring for nutritional complications of bariatric surgery and use of nutritional supplements is a lifelong process. Family physicians should identify patients with a history of bariatric surgery and ensure that those patients are taking the appropriate bariatric nutritional supplements and remain up to date with follow-up testing. Testing for nutritional deficiencies is typically done at 3, 6, 9, and 12 months after surgery and annually thereafter.<sup>114</sup>



TABLE 7: Minimum recommended micronutrient intake for metabolic bariatric surgery procedures. (Copied from reference 101).

Nutrient	Recommended supplementation SG or RYGB	Recommended supplementation BPD-DS, or SADI-S
Vitamin B1 (thiamin)	At least 12 mg oral daily	At least 12 mg oral daily
Vitamin B9 (folate, folic acid)	400 mcg oral daily (800 mcg oral daily for child-bearing women)	400 mcg oral daily (800 mcg oral daily for child-bearing women)
Vitamin B12 (cobalamin; cyanocobalamin synthetic form)	350 mcg oral daily	500 mcg oral daily
Vitamin A (retinol)	5000 IU (1500 mcg)/oral daily	10,000 IU (3000 mcg)/oral daily
Vitamin D (D3, cholecalciferol)	3000 IU (75 mcg)/oral daily	3000 IU (75 mcg)/oral daily
Vitamin E (alpha-tocopherol)	15 mg oral daily	15 mg oral daily
Vitamin K (phylloquinone)	90 mcg oral daily	300 mcg oral daily
Calcium (citrate)	1200 mg oral daily	1800 mg oral daily
Copper	2 mg oral daily	2 mg oral daily
Iron	45 mg oral daily	45 mg oral daily
Zinc <sup>a</sup>	16–22 mg oral daily	16–22 mg oral daily
Vitamin B2 (riboflavin)	200 % DV, (2.6 mg)	200 % DV, (2.6 mg)
Vitamin B3 (niacin)	20 mg daily (125 % DV)	200 % DV, (F: 28 mg; M: 32 mg)
Vitamin B5 (pantothenic acid)	200 % DV, (10 mg)	200 % DV, (10 mg)
Vitamin B6 (pyridoxine)	4 mg daily	4 mg daily
Vitamin B7 (biotin)	200 % DV, (60 mcg)	200 % DV, (60 mcg)
Vitamin C	120 mg daily	180 mg daily

RYGB: roux-en y gastric bypass; SG: sleeve gastrectomy, BPD-DS: biliopancreatic diversion with duodenal switch, SADI-S: single anastomosis duodeno-ileostomy with sleeve gastrectomy; DV: daily value; mg: milligrams; mcg: micrograms; IU: international units; F: female; M: male.

## HOW SHOULD FAMILY PHYSICIANS CODE FOR OBESITY?

Updated International Classification of Disease (ICD) codes for obesity in adult and pediatric patients became effective October 1, 2024. Applicable references include:

1. <https://www.cdc.gov/obesity/media/pdfs/2024/12/adult-partner-promotion-materials-icd-10-codes-508.pdf> (accessed January 2, 2025)
2. <https://www.cdc.gov/obesity/media/pdfs/2024/12/child-partner-promotion-materials-icd-10-codes-508.pdf> (accessed January 2, 2025)
3. <https://obesitymedicine.org/blog/new-icd-10-codes-for-obesity-treatment-advancements-in-accurate-diagnosis-and-care/?form=MG0AV3> (accessed January 14, 2025)
4. <https://www.cdc.gov/growthcharts/extended-bmi.htm> (accessed January 9, 2025)

The current codes that are based on BMI classification of obesity, distinguishing between class 1, class 2, and class 3 obesity (Table 8), provide more precise clinical information than the previous classifications. Recognizing obesity as a complex chronic disease, the updated codes improve the quality of data on the disease of obesity in relation to health consequences and disease burden in adults and children. The previous ICD-10 codes used stigmatizing language with explicit language and outdated perspectives implying that obesity is solely due to excess calories. The current ICD-10 codes remove the stigmatizing and biased language that was used in the previous codes and shift the focus to categorizing obesity according to the current scientific classifications. The updated codes replace the older ICD-10 codes E66.01, E66.09, E66.8, and E66.0. Utilization of older codes may result in claim rejection.

The updated adult E66.XXX codes should be used in conjunction with the Z-codes for BMI. (See Table 9). The Z-codes for BMIs ranging from 20.0-39.9 kg/m<sup>2</sup> are

**TABLE 8: Adult obesity codes and BMI categories.** E-codes are part of the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM), which classifies obesity based on severity. Adult Z-codes are also part of the ICD-10-CM system. E-codes are intended to reflect external causes and Z-codes are intended to reflect factors that may influence health. In the case of obesity, E-codes and Z-codes are reflected by BMI

Obesity Classification	Updated E-Codes	Adult Z-Code	Adult BMI Categories
Class 1 obesity	E66.811	z68.30-34	30-34.9
Class 2 obesity	E66.812	z68.35-39	35-39.9
Class 3 obesity	E66.813	Z68.41-45	≥40

**TABLE 9: Adult BMI and corresponding Z-code.** Z-codes are a nonprocedural category of ICD-10 codes that reflect social, economic, and environmental determinants that affect patient health. Z-codes are typically accompanied by a corresponding procedure code, such as a Current Procedural Terminology (CPT) office visit code (e.g., 99213, 99214, 99215).

Adult BMI (kg/m <sup>2</sup> )	Adult Z-Code
<20	Z68.1
20.0-24.9	Z68.20-Z68.24
25.0-29.9	Z68.25-Z68.29
30.0-34.5	Z68.30-Z68.34
35.0-39.9	Z68.35-Z68.39
40.0-44.9	Z68.41
45.0-49.9	Z68.42
50.0-59.9	Z68.43
60.0-69.9	Z68.44
≥70	Z68.45

determined by combining the Z-code, Z68, with the specific BMI value. When the BMI is below 20 kg/m<sup>2</sup> or above 39.9 kg/m<sup>2</sup>, the Z-code reflects a range of BMIs. For example, if a patient has a BMI of 36.7 kg/m<sup>2</sup>, the appropriate codes would be E66.812 for class 2 obesity and Z68.36 reflecting a BMI of 36 kg/m<sup>2</sup>.

It is the judgement of the authors that the E66 code should reflect the patient's initial or highest BMI, and that this code should remain with the patient, even if the patient experiences subsequent weight reduction that might otherwise reduce the BMI to a lower classification. The rationale for this approach is to reflect that the patient will forever have a past history of obesity, as well as to recognize that the patient is at high risk for weight regain. This approach is commonly used for other chronic health conditions. For example, if a patient is being treated for hypertension, the diagnosis is maintained even if blood pressure is normal with treatment.

This approach also helps mitigate the unreasonable notion that, if a patient achieves successful weight reduction with an AOM, the successful effective AOM should be discontinued. To suggest that effective treatment for obesity should be discontinued once goals are achieved represents a failure to recognize obesity as a disease, in the same way that clinicians readily accept T2DM, hypertension, and dyslipidemia as diseases. In these analogous cases, it would be unusual for a clinician to recommend that once successful treatment of T2DM, hypertension, or dyslipidemia is achieved, then treatment of these metabolic diseases should be discontinued. That said, as weight loss declines, the Z-code should change to reflect the current BMI.

The ICD-10 code update also includes current codes for obesity in pediatric patients. (See Table 10). The E66 codes identify obesity class according to age- and gender-specific BMI in relation to pediatric patients in the 95th percentile

TABLE 10: Pediatric E and Z obesity codes and corresponding BMI categories.

Obesity Classification	Updated E-Codes	Pediatric Z-Code	Pediatric BMI Categories
Class 1 obesity	E66.811	Z68.54	95th percentile to <120% of the 95th percentile.
Class 2 obesity	E66.812	Z68.55	≥120% of the 95th percentile to <140% of the 95th percentile.
Class 3 obesity	E66.813	Z68.56	≥140% of the 95th percentile.

based on BMI-for-age growth charts.<sup>117</sup> For pediatric patients, there is a separate set of Z-codes corresponding to each of the three classes of obesity. As with the adult changes, the current obesity codes for pediatric patients provide greater clinical detail with respect to the child's obesity classification.

Some key steps that family physicians can take to implement the current codes include:

1. Utilize the current obesity ICD-10 codes for all relevant encounters
2. Update electronic health record by removing the old codes and replacing them with the current ICD-10 codes for obesity plus associated descriptions
3. Educate clinical and billing staff on the current ICD-10 obesity codes and how to use them
4. Communicate with patients utilizing clinically relevant terms avoiding bias language that stigmatizes the patient with obesity

CONCLUSION

Obesity is a chronic, relapsing, and treatable disease. Obesity and its complications are the most common cause of nontraumatic office visits in primary care. The treatment of obesity can improve cardiometabolic risk factors and other metabolic complications (e.g., MASH), reduce the risk of CVD, cancer, and potentially reduce all-cause mortality. Family physicians are often the first line of treatment and are well positioned to provide obesity care by either implementing a treatment plan or referring the patient to qualified health professionals for nutritional therapy, physical activity, behavioral modification, pharmacotherapy, or bariatric procedures. The advent of newer highly effective AOMs provides obesity treatment options for family physicians, but medical therapy must be combined with the appropriate lifestyle changes to optimize favorable obesity treatment outcomes.

Takeaway messages regarding primary care management of obesity:

- Obesity is a disease that, beyond its fat mass complications, is a major contributor to the most common cardiometabolic abnormalities encountered in primary care (e.g., high blood glucose, high blood pressure, high atherogenic lipids, and CVD).
- Family physicians are often the first line of treatment in the healthcare setting, affording the opportunity for early intervention to prevent and/or treat overweight and/or obesity.
- Barriers that impair optimal care of patients with obesity in primary care include failure to recognize obesity as a disease, lack of accurate diagnosis, insufficient access to obesity treatment resources, and the adverse impact of bias, stigma, and discrimination.
- Beyond the importance of the primary care clinician, the clinician office staff can often play an important role in optimizing the management of patients with obesity.
- Among patients living with obesity, body fat reduction can improve CVD risk factors, reduce the risk of CVD, and improve quality of life.
- Optimal management of patients with obesity includes the four pillars of nutrition therapy, physical activity, behavior modification, and medical interventions (AOMs and bariatric procedures).
- Despite the challenges of inadequate training, insufficient time, and lack of reimbursement, there are practical tools and approaches that are available regarding these four pillars, which may better allow primary care clinicians to improve the health and lives of patients with obesity.
- Towards the goal of optimal care of patients with obesity, primary care clinicians should have a working knowledge of the risks and benefits of AOMs—especially those with proven health outcomes benefits.
- Primary care clinicians should also have a working knowledge of the risks and benefits of bariatric procedures, especially regarding long-term clinical and laboratory follow-up.

TRANSPARENCY AND GROUP COMPOSITION<sup>118</sup>

The authors reflect a mixed group of experts in obesity science and primary care. NP, HP, SH, and CV are members of both OMA and ACOFP. BR and SP are members of ACOFP. HEB is a member of OMA.

AUTHOR CONTRIBUTIONS

NP was responsible for drafting the topics of the initial draft. All of the authors engaged in review and editing. HEB served as medical writer. All authors approved the final draft.

## MANAGING DISCLOSURES AND DUALITIES OF INTEREST

Authors of this joint expert review received no payment for their writing, editing, and publishing work. While editors of journals who are listed as authors received payment for their roles as editors, they did not receive payment for their participation as authors.

## INDIVIDUAL DISCLOSURES

Dr. Nicholas Pennings has served as a consultant for Abbott, speaker for Novo Nordisk, and an independent contractor with Medifast.

Dr. Catherine Varney has served on a primary care advisory board for Eli Lilly.

Dr. Shaun Hines has no financial disclosures.

Dr. Bernadette Riley has no financial disclosures.

Dr. Patricia Happel has no financial disclosures.

Student doctor Samir Patel has no financial disclosures.

Dr. Harold Bays' research site institution has received research grants from 89bio, Allergan, Alon MedTech/Epitomee, Aligos Therapeutics, Altimune, Amgen, Anji Pharmaceuticals, AbbVie, AstraZeneca, BioAge Labs, Bionime, Boehringer Ingelheim, Carmot Therapeutics, Chorus/BioAge, Eli Lilly, Esperion, Evidera, Fractyl Health, GlaxoSmithKline, High Tide Therapeutics, Home Access Health, Horizon, Ionis Pharmaceuticals, Kallyope, LG Chem, Madrigal Pharmaceuticals, Merck, Mineralys Therapeutics, NewAmsterdam Pharma, Novartis, Novo Nordisk, Pfizer, Regeneron, Satsuma Pharmaceuticals, Selecta Biotech, Shionogi, Skye Bioscience/Birdrock Laboratories, TIMI Pharmaceuticals, Veru, Viking Therapeutics, and Vivus. Dr. Harold Bays has served as a consultant/advisor for 89bio, Altimune, Amgen, Boehringer Ingelheim, Kiniksa Pharmaceuticals, High Tide Therapeutics, Lilly, Novo Nordisk, Regeneron, Veru, Zomagen Biosciences, and ZyVersa Therapeutics.

## FUNDING

Preparation of this manuscript received no funding.

## EVIDENCE

The content of this manuscript is supported by citations, which are listed in the References section, as well as the practical clinical experiences of the authors.

## ETHICS REVIEW

This submission did not involve experimentation of human test subjects or volunteers. Authors who concomitantly served as journal editors for *Obesity Pillars* or *Osteopathic Family Physician Journal* were not involved in editorial

decisions or the peer-review process. Journal editorial decisions and peer-review management were delegated to nonauthor society members or nonauthor journal editors.

## PEER REVIEW

This joint expert review underwent peer review according to the policies of the participating organizations (e.g., journal reviewers and societal leadership). Additionally, this manuscript was reviewed by the leadership of ACOFP and OMA.

## DECLARATION OF ARTIFICIAL INTELLIGENCE (AI) AND AI-ASSISTED TECHNOLOGIES IN THE WRITING PROCESS

AI was used for suggestions regarding topic headings and word phrasing, but not used in the writing of the text nor creation of its figures.

## CONCLUSIONS AND RECOMMENDATIONS

This joint expert review is intended to be an educational tool that incorporates the current medical science and the clinical experiences of obesity specialists, primary care clinicians, and/or those engaged in obesity management. The intent is to better facilitate and improve the clinical care and management of patients with obesity. This joint expert review should not be interpreted as "rules" and/or directives regarding the medical care of an individual patient. The decision regarding the optimal care of the patient with overweight/preobesity and obesity is best reliant on a patient-centered approach, managed by the clinician tasked with directing an individual treatment plan that is in the best interest of the individual patient.

## UPDATING

This joint expert review may require future updates. The timing of such an update will be determined by the respective societies authoring this document.

## DISCLAIMER AND LIMITATIONS

This joint expert review was developed to assist healthcare professionals in providing care for patients with preobesity and obesity based on the best available evidence. In areas regarding inconclusive or insufficient scientific evidence, the authors used their professional judgment. This joint expert review is intended to represent the state of obesity medicine at the time of publication. Thus, this joint expert review is not a substitute for maintaining awareness of emerging new science. Finally, decisions by clinicians and healthcare professionals to apply the principles in this joint expert review are best made by considering local resources, individual patient circumstances, patient agreement, and knowledge of federal, state, and local laws and guidance.



## REFERENCES

1. Bays HE, Golden A, Tondt J. Thirty obesity myths, misunderstandings, and/or oversimplifications: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars*. 2022;3:100034. doi: 10.1016/j.obpill.2022.100034.
2. Fitch AK, Bays HE. Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars*. 2022;1:100004. doi: 10.1016/j.obpill.2021.100004.
3. Bays HE, Bindlish S, Clayton TL. Obesity, diabetes mellitus, and cardiometabolic risk: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023. *Obes Pillars*. 2023;5:100056. doi: 10.1016/j.obpill.2023.100056.
4. Clayton TL, Fitch A, Bays HE. Obesity and hypertension: Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023. *Obesity Pillars*. 2023;8:100083. doi: 10.1016/j.obpill.2023.100083.
5. Bays HE, Kirkpatrick C, Maki KC, et al. Obesity, dyslipidemia, and cardiovascular disease: a joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. *Obes Pillars*. 2024;10:100108. doi: 10.1016/j.obpill.2024.100108.
6. Bays H. Adiposopathy, "sick fat," Ockham's razor, and resolution of the obesity paradox. *Curr Atheroscler Rep*. 2014;16(5):409. doi: 10.1007/s11883-014-0409-1.
7. Bindlish S, Ng J, Ghush W, Fitch A, Bays HE. Obesity, thrombosis, venous disease, lymphatic disease, and lipedema: an obesity medicine association (OMA) Clinical Practice Statement (CPS) 2023. *Obes Pillars*. 2023;8:100092. doi: 10.1016/j.obpill.2023.100092.
8. Lazarus E, Bays HE. Cancer and obesity: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars*. 2022;3:100026. doi: 10.1016/j.obpill.2022.100026.
9. World Health Organization. Obesity and overweight. <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>.
10. Centers for Disease Control and Prevention. Overweight and obesity. Adult obesity facts. <https://www.cdc.gov/obesity/data/adult.html>
11. Woods T, Miljkovic T. Modeling the economic cost of obesity risk and its relation to the health insurance premium in the United States: a state level analysis. *Risks*. 2022;10(10):197. doi: 10.3390/risks10100197.
12. Anekwe CV, Jarrell AR, Townsend MJ, Gaudier GI, Hiserodt JM, Stanford FC. Socioeconomics of obesity. *Curr Obes Rep*. 2020;9(3):272–279. doi: 10.1007/s13679-020-00398-7.
13. Bays HE, Munoz-Mantilla DX, Morgan R, Nwizu C, Garcia TT. Obesity Pillars roundtable: obesity and diversity. *Obes Pillars*. 2022;1:100008. doi: 10.1016/j.obpill.2021.100008.
14. Bays HE, Gonsahn-Bollie S, Younglove C, Wharton S. Obesity Pillars roundtable: body mass index and body composition in Black and female individuals. Race-relevant or racist? Sex-relevant or sexist? *Obes Pillars*. 2022;4:100044. doi: 10.1016/j.obpill.2022.100044.
15. Bays HE, Shrestha A, Niranjani V, Khanna M, Kambhamettu L. Obesity Pillars roundtable: obesity and south Asians. *Obes Pillars*. 2022;1:100006. doi: 10.1016/j.obpill.2021.100006.
16. Bays HE, Ng J, Sicut J, Look M. Obesity Pillars roundtable: obesity and east Asians. *Obes Pillars*. 2022;2:100011. doi: 10.1016/j.obpill.2022.100011.
17. Bays HE, Antoun J, Censani M, Bailony R, Alexander L. Obesity Pillars roundtable: obesity and individuals from the Mediterranean region and Middle East. *Obes Pillars*. 2022;2:100013. doi: 10.1016/j.obpill.2022.100013.
18. Tsai AG, Abbo ED, Ogden LG. The time burden of overweight and obesity in primary care. *BMC Health Serv Res*. 2011;11:191. doi: 10.1186/1472-6963-11-191.
19. Martin B-J, Chen G, Graham M, Quan H. Coding of obesity in administrative hospital discharge abstract data: accuracy and impact for future research studies. *BMC Health Serv Res*. 2014;14:70. doi: 10.1186/1472-6963-14-70.
20. Mainous AG III, Xie Z, Dickmann SB, Medley JF, Hong YR. Documentation and treatment of obesity in primary care physician office visits: the role of the patient-physician relationship. *J Am Board Fam Med*. 2023;36(2):325–332. doi: 10.3122/jabfm.2022.220297R1.
21. Mattar A, Carlston D, Sariol G, et al. The prevalence of obesity documentation in primary care electronic medical records. Are we acknowledging the problem? *Appl Clin Inform*. 2017;8(1):67–79. doi: 10.4338/ACI-2016-07-RA-0115.
22. Cierns EL, Joshi V, Cuddeback JK, Kushner RF, Horn DB, Garvey WT. Diagnosing obesity as a first step to weight loss: an observational study. *Obesity (Silver Spring)*. 2020;28(12):2305–2309. doi: 10.1002/oby.22954.
23. Pennings N, Golden L, Yashi K, Tondt J, Bays HE. Sleep-disordered breathing, sleep apnea, and other obesity-related sleep disorders: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 20. *Obes Pillars*. 2022;4:100043. doi: 10.1016/j.obpill.2022.100043.
24. Christensen SM, Varney C, Gupta V, Wenz L, Bays HE. Stress, psychiatric disease, and obesity: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars*. 2022;4:100041. doi: 10.1016/j.obpill.2022.100041.
25. Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. *Circulation*. 2021;143(21):e984–e1010. doi: 10.1161/CIR.0000000000000973.
26. Lega IC, Lipscombe LL. Review: diabetes, obesity, and cancer-pathophysiology and clinical implications. *Endocr Rev*. 2020;41(1):bnz014. doi: 10.1210/edrev/bnz014.
27. Kramer ES, Deffenbacher BM, Staton EM, Smith PM, Summers Holtrop JP. The weight-prioritized visit: an idea whose time has come. *Fam Pract Manag*. 2023;30(6):19–25.
28. Grover SA, Kaouache M, Rempel P, et al. Years of life lost and healthy life-years lost from diabetes and cardiovascular disease in overweight and obese people: a modelling study. *Lancet Diabetes Endocrinol*. 2015;3(2):114–122. doi: 10.1016/S2213-8587(14)70229-3.
29. Peto R, Whitlock G, Jha P. Effects of obesity and smoking on U.S. life expectancy. *N Engl J Med*. 2010;362(9):855–856; author reply 6–7. doi: 10.1056/NEJMc1000079.
30. Prospective Studies Collaboration; Whitlock G, Lewington S, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. *Lancet*. 2009;373(9669):1083–1096. doi: 10.1016/S0140-6736(09)60318-4.
31. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*. 2002;346(6):393–403. doi: 10.1056/NEJMoa012512.
32. Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. *Curr Obes Rep*. 2017;6(2):187–194. doi: 10.1007/s13679-017-0262-y.
33. Greaney ML, Cohen SA, Xu F, Ward-Ritacco CL, Riebe D. Healthcare provider counselling for weight management behaviours among adults with overweight or obesity: a cross-sectional analysis of National Health and Nutrition Examination Survey, 2011–2018. *BMJ Open*. 2020;10(11):e039295. doi: 10.1136/bmjopen-2020-039295.



34. Burridge K, Christensen SM, Golden A, Ingersoll AB, Tondt J, Bays HE. Obesity history, physical exam, laboratory, body composition, and energy expenditure: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars*. 2022;1:100007. doi: 10.1016/j.obpill.2021.100007.
35. Burridge K, Christensen SM, Golden A, Ingersoll AB, Tondt J, Bays HE. Obesity history, physical exam, laboratory, body composition, and energy expenditure: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars*. 2022;1:100007. doi: 10.1016/j.obpill.2021.100007.
36. Bays H. Central obesity as a clinical marker of adiposopathy; increased visceral adiposity as a surrogate marker for global fat dysfunction. *Current Opin Endocrinol Diabetes Obes*. 2014;21(5):345–351. doi: 10.1097/MED.000000000000093.
37. Gudzone KA, Bennett WL, Cooper LA, Bleich SN. Patients who feel judged about their weight have lower trust in their primary care providers. *Patient Educ Couns*. 2014;97(1):128–131. doi: 10.1016/j.pec.2014.06.019.
38. Major B, O'Brien LT. The social psychology of stigma. *Annu Rev Psychol*. 2005;56:393–421. doi: 10.1146/annurev.psych.56.091103.070137.
39. Schvey NA, Puhl RM, Brownell KD. The impact of weight stigma on caloric consumption. *Obesity (Silver Spring)*. 2011;19(10):1957–1962. doi: 10.1038/oby.2011.204.
40. Phelan SM, Bauer KW, Bradley D, et al. A model of weight-based stigma in health care and utilization outcomes: evidence from the learning health systems network. *Obes Sci Pract*. 2022;8(2):139–146. doi: 10.1002/osp4.553.
41. Brown CF, Zvenych T, Paul E, Golden L, Varney C, Bays HE. Obesity and advocacy: a joint clinical perspective and expert review from the Obesity Medicine Association and the Obesity Action Coalition. *Obes Pillars*. 2024;11:100119. doi: 10.1016/j.obpill.2024.100119.
42. Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective obesity care: results from the National ACTION study. *Obesity (Silver Spring)*. 2018;26(1):61–69. doi: 10.1002/oby.22054.
43. Doerrmann C, Oancea SC, Selya A. The association between hours spent at work and obesity status: results from NHANES 2015 to 2016. *Am J Health Promot*. 2020;34(4):359–365. doi: 10.1177/0890117119897189.
44. Verde L, Frias-Toral E, Cardenas D. Editorial: environmental factors implicated in obesity. *Front Nutr*. 2023;10:1171507. doi: 10.3389/fnut.2023.1171507.
45. Kim TJ, von dem Knesebeck O. Income and obesity: what is the direction of the relationship? A systematic review and meta-analysis. *BMJ Open*. 2018;8(1):e019862. doi: 10.1136/bmjopen-2017-019862.
46. Fitch A, Horn DB, Still CD, et al. Obesity medicine as a subspecialty and United States certification - a review. *Obes Pillars*. 2023;6:100062. doi: 10.1016/j.obpill.2023.100062.
47. Gallagher C, Corl A, Dietz WH. Weight can't wait: a guide to discussing obesity and organizing treatment in the primary care setting. *Obesity (Silver Spring)*. 2021;29(5):821–824. doi: 10.1002/oby.23154.
48. Oshman L, Othman A, Furst W, et al. Primary care providers' perceived barriers to obesity treatment and opportunities for improvement: a mixed methods study. *PloS One*. 2023;18(4):e0284474. doi: 10.1371/journal.pone.0284474.
49. Bays HE, Francavilla Brown C, Fitch A. Universal prior authorization template for glucagon like peptide-1 based anti-obesity medications: an Obesity Medicine Association proposal. *Obes Pillars*. 2023;8:100079. doi: 10.1016/j.obpill.2023.100079.
50. Freshwater M, Christensen S, Oshman L, Bays HE. Behavior, motivational interviewing, eating disorders, and obesity management technologies: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars*. 2022;2:100014. doi: 10.1016/j.obpill.2022.100014.
51. Karjoo S, Auriemma A, Fraker T, Bays HE. Nonalcoholic fatty liver disease and obesity: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars*. 2022;3:100027. doi: 10.1016/j.obpill.2022.100027.
52. Bays HE, Fitch A, Christensen S, Burridge K, Tondt J. Anti-obesity medications and investigational agents: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars*. 2022;2:100018. doi: 10.1016/j.obpill.2022.100018.
53. Bays HE. Adiposopathy is "sick fat" a cardiovascular disease? *J Am Coll Cardiol*. 2011;57(25):2461–2473. doi: 10.1016/j.jacc.2011.02.038.
54. Arsenault BJ, Carpentier AC, Poirier P, Despres JP. Adiposity, type 2 diabetes and atherosclerotic cardiovascular disease risk: use and abuse of the body mass index. *Atherosclerosis*. 2024;394:117546. doi: 10.1016/j.atherosclerosis.2024.117546.
55. Bliddal H, Bays H, Czernichow S, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. *N Engl J Med*. 2024;391(17):1573–1583. doi: 10.1056/NEJMoa2403664.
56. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity, kidney dysfunction and hypertension: mechanistic links. *Nat Rev Nephrol*. 2019;15(6):367–385. doi: 10.1038/s41581-019-0145-4.
57. Darlenski R, Mihaylova V, Handjieva-Darlenska T. The link between obesity and the skin. *Front Nutr*. 2022;9:855573. doi: 10.3389/fnut.2022.855573.
58. Griaude DH, Turner CD, Othman A, et al. A primary care-based weight navigation program. *JAMA Netw Open*. 2024;7(5):e2412192. doi: 10.1001/jamanetworkopen.2024.12192.
59. Wadden TA, Volger S, Tsai AG, et al. Managing obesity in primary care practice: an overview with perspective from the POWER-UP study. *Int J Obes (Lond)*. 2013;37(suppl 1):S3–S11. doi: 10.1038/ijo.2013.90.
60. Bays HE, Burridge K, Richards J, Fitch A. Obesity Pillars roundtable: excessive weight reduction with highly effective anti-obesity medications (heAOMs). *Obes Pillars*. 2022;4:100039. doi: 10.1016/j.obpill.2022.100039.
61. Shetye B, Hamilton FR, Bays HE. Bariatric surgery, gastrointestinal hormones, and the microbiome: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars*. 2022;2:100015. doi: 10.1016/j.obpill.2022.100015.
62. Morgan-Bathke M, Raynor HA, Baxter SD, et al. Medical nutrition therapy interventions provided by dietitians for adult overweight and obesity management: an Academy of Nutrition and Dietetics Evidence-Based Practice Guideline. *J Acad Nutr Diet*. 2023;123(3):520–545. doi: 10.1016/j.jand.2022.11.014.
63. Varkevisser RDM, van Stralen MM, Kroeze W, Ket JCF, Steenhuis IHM. Determinants of weight loss maintenance: a systematic review. *Obes Rev*. 2019;20(2):171–211. doi: 10.1111/obr.12772.
64. Alexander L, Christensen SM, Richardson L, et al. Nutrition and physical activity: an Obesity Medicine Association (OMA) Clinical Practice Statement 2022. *Obes Pillars*. 2022;1:100005. doi: 10.1016/j.obpill.2021.100005.
65. Gwin JA, Church DD, Wolfe RR, Ferrando AA, Pasiakos SM. Muscle protein synthesis and whole-body protein turnover responses to ingesting essential amino acids, intact protein, and protein-containing mixed meals with considerations for energy deficit. *Nutrients*. 2020;12(8):2457. doi: 10.3390/nu12082457.

66. 66. Shefflette A, Patel N, Caruso J. Mitigating sarcopenia with diet and exercise. *Int J Environ Res Public Health*. 2023;20(17):6652. doi: 10.3390/ijerph20176652.
67. 67. Winzeler B, da Conceicao I, Refardt J, Sailer CO, Dutilh G, Christ-Crain M. Effects of glucagon-like peptide-1 receptor agonists on fluid intake in healthy volunteers. *Endocrine*. 2020;70(2):292–298. doi: 10.1007/s12020-020-02394-2.
68. Nakhleh A, Shehadeh N, Mansour B. GLP-1 receptor agonists may enhance the effects of desmopressin in individuals with AVP deficiency: a case series and proposed mechanism. *Pituitary*. 2024;27(5):731–736. doi: 10.1007/s11102-024-01451-7.
69. Crowley J, Ball L, Hiddink GJ. Nutrition care by primary-care physicians: advancing our understanding using the COM-B framework. *Public Health Nutr*. 2020;23(1):41–52. doi: 10.1017/S1368980019003148.
70. Bays HE, Kulkarni A, German C, et al. Ten things to know about ten cardiovascular disease risk factors - 2022. *Am J Prev Cardiol*. 2022;10:100342. doi: 10.1016/j.ajpc.2022.100342.
71. Wadden TA, Tronieri JS, Butryn ML. Lifestyle modification approaches for the treatment of obesity in adults. *Am Psychol*. 2020;75(2):235–251. doi: 10.1037/amp0000517.
72. LeBlanc ES, Patnode CD, Webber EM, Redmond N, Rushkin M, O'Connor EA. Behavioral and pharmacotherapy weight loss interventions to prevent obesity-related morbidity and mortality in adults: updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA*. 2018;320(11):1172–1191. doi: 10.1001/jama.2018.7777.
73. Toussi R, Fujioka K, Coleman KJ. Pre- and postsurgery behavioral compliance, patient health, and postbariatric surgical weight loss. *Obesity (Silver Spring)*. 2009;17(5):996–1002. doi: 10.1038/oby.2008.628.
74. Chao AM, Moore M, Wadden TA. The past, present, and future of behavioral obesity treatment. *Int J Obes (Lond)*. 2025;49(2):196–205. doi: 10.1038/s41366-024-01525-3.
75. Whigham LD, Messiah SE, Balasubramanian BA, Dhurandhar NV. The essential role of primary care providers in obesity management. *Int J Obes (Lond)*. 2023;47(4):249–250. doi: 10.1038/s41366-023-01268-7.
76. Cardel MI, Ross KM, Butryn M, et al. Acceptance-based therapy: the potential to augment behavioral interventions in the treatment of type 2 diabetes. *Nutr Diabetes*. 2020;10(1):3. doi: 10.1038/s41387-020-0106-9.
77. Alexander L, Christensen SM, Richardson L, et al. Nutrition and physical activity: an Obesity Medicine Association (OMA) Clinical Practice Statement 2022. *Obes Pillars*. 2022;1:100005. doi: 10.1016/j.obpill.2021.100005.
78. Creasy SA, Lang W, Tate DF, Davis KK, Jakicic JM. Pattern of daily steps is associated with weight loss: secondary analysis from the Step-Up randomized trial. *Obesity (Silver Spring)*. 2018;26(6):977–984. doi: 10.1002/oby.22171.
79. Banach M, Lewek J, Surma S, et al. The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis. *Eur J Prev Cardiol*. 2023;30(18):1975–1985. doi: 10.1093/eurjpc/zwad229.
80. Oppert JM, Bellicha A, van Baak MA, et al. Exercise training in the management of overweight and obesity in adults: synthesis of the evidence and recommendations from the European Association for the Study of Obesity Physical Activity Working Group. *Obes Rev*. 2021;22(suppl 4):e13273. doi: 10.1111/obr.13273.
81. Lobelo F, Rohm Young D, Sallis R, et al. Routine assessment and promotion of physical activity in healthcare settings: a scientific statement from the American Heart Association. *Circulation*. 2018;137(18):e495–e522. doi: 10.1161/CIR.0000000000000559.
82. Lobelo F, Muth ND, Hanson S, et al. Physical activity assessment and counseling in pediatric clinical settings. *Pediatrics*. 2020;145(3):e20193992. doi: 10.1542/peds.2019-3992.
83. Baker R, Freeman GK, Haggerty JL, Bankart MJ, Nockels KH. Primary medical care continuity and patient mortality: a systematic review. *Br J Gen Pract*. 2020;70(698):e600–e611. doi: 10.3399/bjgp20X712289.
84. 84. Pereira Gray DJ, Sidaway-Lee K, White E, Thorne A, Evans PH. Continuity of care with doctors-a matter of life and death? A systematic review of continuity of care and mortality. *BMJ Open*. 2018;8(6):e021161. doi: 10.1136/bmjopen-2017-021161.
85. Koh H, Kwon S, Cho B. Association of primary care physician supply with population mortality in South Korea: a pooled cross-sectional analysis. *Korean J Fam Med*. 2024;45(2):105–115. doi: 10.4082/kjfm.23.0156.
86. Fitch A, Alexander L, Brown CF, Bays HE. Comprehensive care for patients with obesity: an Obesity Medicine Association Position Statement. *Obes Pillars*. 2023;7:100070. doi: 10.1016/j.obpill.2023.100070.
87. Bays HE, Lazarus E, Primack C, Fitch A. Obesity pillars roundtable: phentermine - past, present, and future. *Obes Pillars*. 2022;3:100024. doi: 10.1016/j.obpill.2022.100024.
88. Lewis KH, Fischer H, Ard J, et al. Safety and effectiveness of longer-term phentermine Use: clinical outcomes from an electronic health record cohort. *Obesity (Silver Spring)*. 2019;27(4):591–602. doi: 10.1002/oby.22430.
89. Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. *Obesity*. 2013;21(11):2163–171. doi: 10.1002/oby.20584.
90. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2010;376(9741):595–605. doi: 10.1016/s0140-6736(10)60888-4.
91. Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). *Obesity (Silver Spring)*. 2013;21(5):935–943. doi: 10.1002/oby.20309.
92. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. *N Engl J Med*. 2021;384(11):989–1002. doi: 10.1056/NEJMoa2032183.
93. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. *N Engl J Med*. 2023;389(24):2221–2232. doi: 10.1056/NEJMoa2307563.
94. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. *N Engl J Med*. 2022;387(3):205–216. doi: 10.1056/NEJMoa2206038.
95. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. *N Engl J Med*. 2024;391(13):1193–1205. doi: 10.1056/NEJMoa2404881.
96. Fitch A, Auriemma A, Bays HE. Compounded peptides: an Obesity Medicine Association position statement. *Obes Pillars*. 2023;6:100061. doi: 10.1016/j.obpill.2023.100061.
97. Bays HE, Fitch A, Francavilla Brown C, Younglove C, Christensen SM, Alexander LC. Frequently asked questions to the 2023 obesity medicine association position statement on compounded peptides: a call for action. *Obes Pillars*. 2024;11:100122. doi: 10.1016/j.obpill.2024.100122.

98. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. *JAMA*. 2021;325(14):1414–1225. doi: 10.1001/jama.2021.3224.
99. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. *JAMA*. 2024;331(1):38–48. doi: 10.1001/jama.2023.24945.
100. Puhl RM. Weight stigma and barriers to effective obesity care. *Gastroenterol Clin North Am*. 2023;52(2):417–428. doi: 10.1016/j.gtc.2023.02.002.
101. Benson-Davies S, Frederiksen K, Patel R. Bariatric nutrition and evaluation of the metabolic surgical patient: update to the 2022 Obesity Medicine Association (OMA) bariatric surgery, gastrointestinal hormones, and the microbiome clinical practice statement (CPS). *Obes Pillars*. 2025;13:100154. doi: 10.1016/j.obpill.2024.100154.
102. Arterburn DE, Telem DA, Kushner RF, Courcoulas AP. Benefits and risks of bariatric surgery in adults: a review. *JAMA*. 2020;324(9):879–887. doi: 10.1001/jama.2020.12567.
103. de la Cruz-Munoz N, Xie L, Quiroz HJ, et al. Long-term outcomes after adolescent bariatric surgery. *J Am Coll Surg*. 2022;235(4):592–602. doi: 10.1097/XCS.0000000000000325.
104. Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) indications for metabolic and bariatric surgery. *Obes Surg*. 2023;33(1):3–14. doi: 10.1007/s11695-022-06332-1.
105. Hardt K, Wappler F. Anesthesia for morbidly obese patients. *Dtsch Arztebl Int*. 2023;120(46):779–785. doi: 10.3238/arztebl.m2023.0216.
106. Xanthakos SA, Khoury JC, Inge TH, et al. Nutritional risks in adolescents after bariatric surgery. *Clin Gastroenterol Hepatol*. 2020;18(15):1070–1081.e5. doi: 10.1016/j.cgh.2019.10.048.
107. Doumouras AG, Wong JA, Paterson JM, et al. Bariatric surgery and cardiovascular outcomes in patients with obesity and cardiovascular disease. *Circulation*. 2021;143(15):1468–1480. doi: 10.1161/CIRCULATIONAHA.120.052386.
108. Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. *N Engl J Med*. 2007;357(8):741–752. doi: 10.1056/NEJMoa066254.
109. Chandrakumar H, Khatun N, Gupta T, Graham-Hill S, Zhyvotovska A, McFarlane SI. The effects of bariatric surgery on cardiovascular outcomes and cardiovascular mortality: a systematic review and meta-analysis. *Cureus*. 2023;15(2):e34723. doi: 10.7759/cureus.34723.
110. Kirwan JP, Courcoulas AP, Cummings DE, et al. Diabetes remission in the alliance of randomized trials of medicine versus metabolic surgery in type 2 diabetes (ARMMS-T2D). *Diabetes Care*. 2022;45(7):1574–1583. doi: 10.2337/dc21-2441.
111. Auge M, Dejjardin O, Menahem B, et al. Analysis of the lack of follow-up of bariatric surgery patients: experience of a reference center. *J Clin Med*. 2022;11(21):6310. doi: 10.3390/jcm11216310.
112. Schlottmann F, Baz C, Pirzada A, Masrur MA. Postoperative follow-up compliance: the Achilles' heel of bariatric surgery. *Obes Surg*. 2023;33(9):2945–2948. doi: 10.1007/s11695-023-06769-y.
113. Kaur S, Nimmala S, Singhal V, et al. Bone changes post-sleeve gastrectomy in relation to body mass and hormonal changes. *Eur J Endocrinol*. 2023;189(3):346–354. doi: 10.1093/ajendo/lvad121.
114. Mechanick JL, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: Cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. *Endocr Pract*. 2019;25(12):1346–1359. doi: 10.4158/GL-2019-0406.
115. Makhososi BR, Ghobadi P, Otaghi M, Tardeh Z. Impact of bariatric surgery on infertility in obese women: a systematic review and meta-analysis. *Ann Med Surg (Lond)*. 2024;86(12):7042–7048. doi: 10.1097/MS9.0000000000002657.
116. Verras GI, Mulita F, Pouwels S, et al. Outcomes at 10-year follow-up after Roux-en-Y gastric bypass, biliopancreatic diversion, and sleeve gastrectomy. *J Clin Med*. 2023;12(15):4973. doi: 10.3390/jcm12154973.
117. Cuda SE, Censani M. Assessment, differential diagnosis, and initial clinical evaluation of the pediatric patient with obesity: an Obesity Medical Association (OMA) Clinical Practice Statement 2022. *Obes Pillars*. 2022;1:100010. doi: 10.1016/j.obpill.2022.100010.
118. Graham R, Mancher M, Miller Wolman D, Greenfield S, Steinberg E. Clinical practice guidelines we can trust. National Academies Press; 2011. doi: 10.17226/13058